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BACKGROUND: Acute COVID-19–related myocardial, pulmonary, and vascular pathology and how these relate to each other
remain unclear. To our knowledge, no studies have used complementary imaging techniques, including molecular imaging, to elucidate this. We used multimodality imaging and biochemical sampling in vivo to identify the pathobiology of acute
COVID-19. Specifically, we investigated the presence of myocardial inflammation and its association with coronary artery
disease, systemic vasculitis, and pneumonitis.
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METHODS AND RESULTS: Consecutive patients presenting with acute COVID-19 were prospectively recruited during hospital
admission in this cross-sectional study. Imaging involved computed tomography coronary angiography (identified coronary
disease), cardiac 2-deoxy-2-[fluorine-18]fluoro-D-glucose positron emission tomography/computed tomography (identified
vascular, cardiac, and pulmonary inflammatory cell infiltration), and cardiac magnetic resonance (identified myocardial disease) alongside biomarker sampling. Of 33 patients (median age 51 years, 94% men), 24 (73%) had respiratory symptoms,
with the remainder having nonspecific viral symptoms. A total of 9 patients (35%, n=9/25) had cardiac magnetic resonance–
defined myocarditis. Of these patients, 53% (n=5/8) had myocardial inflammatory cell infiltration. A total of 2 patients (5%) had
elevated troponin levels. Cardiac troponin concentrations were not significantly higher in patients with and without myocarditis
(8.4 ng/L [interquartile range, IQR: 4.0–55.3] versus 3.5 ng/L [IQR: 2.5–5.5]; P=0.07) or myocardial cell infiltration (4.4 ng/L [IQR:
3.4–8.3] versus 3.5 ng/L [IQR: 2.8–7.2]; P=0.89). No patients had obstructive coronary artery disease or vasculitis. Pulmonary
inflammation and consolidation (percentage of total lung volume) was 17% (IQR: 5%–31%) and 11% (IQR: 7%–18%), respectively. Neither were associated with the presence of myocarditis.
CONCLUSIONS: Myocarditis was present in a third patients with acute COVID-19, and the majority had inflammatory cell infiltration. Pneumonitis was ubiquitous, but this inflammation was not associated with myocarditis. The mechanism of cardiac
pathology is nonischemic and not attributable to a vasculitic process.
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CLINICAL PERSPECTIVE
What Is New?

• This is a prospective multimodality imaging
study of acute COVID-19 in an unselected population presenting to hospital.
• Cardiac magnetic resonance, cardiac and vascular molecular positron emission tomography
imaging, and computed tomography coronary
angiography in conjunction with biochemical
biomarkers were used to comprehensively phenotype patients with acute COVID-19.

What Are the Clinical Implications?

• Rates of myocarditis were high in an unselected
population of acute COVID-19 and may occur in
the absence of biochemical markers of injury.
• Cardiac involvement in COVID-19 may not be appreciated clinically without imaging and can occur
in the absence of severe pulmonary involvement.
• Vasculitis or coronary artery thrombosis are not
the cause of myocardial injury.

Nonstandard Abbreviations and Acronyms
18F-FDG
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CTCA
hs-cTnI
LGE
T1
T2
TBR

C

2-deoxy-2-[fluorine-18]
fluoro-D-glucose
computed tomography coronary
angiography
high-sensitivity cardiac troponin I
late gadolinium enhancement
longitudinal relaxation time
horizontal relaxation time
target-to-background ratio

OVID-19 has been mostly associated with pulmonary injury, but its association with cardiac and vascular pathobiology remains poorly understood.1–3
Patients with cardiac involvement are at a higher risk of
mortality, with 8% to 28% of patients showing biochemical evidence of myocardial injury.4
2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG)
positron emission tomography (PET)/computed tomography (CT) can identify cellular inflammation in pulmonary, cardiac, and vascular tissues, but prospective
studies in COVID-19 remain limited.5–7 Although cardiac
magnetic resonance (CMR)1–3 and chest CT imaging
in COVID-19 have been conducted,8 these have been
limited to the recovery phase and restricted to a single
modality. As such, these studies were unable to differentiate ischemic from nonischemic cardiac pathology.
A multisystem inflammatory syndrome in children with
myocarditis and cardiac impairment as hallmarks of

the presentation has been described.9 Whether similar
mechanisms of cardiac and vascular injuries occur in
adults with acute COVID-19 remains unknown. Finally,
it is unknown if myocarditis can develop with only minimal pulmonary involvement.
Using CMR, CT coronary angiography (CTCA),10 and
18F-FDG-PET/CT5–7 imaging during acute COVID-19
infection, we investigated in vivo pathobiology of the
myocardium, arterial vasculature, and pulmonary parenchyma. We hypothesized that myocardial or pulmomary inflammation and injury could be described
by CMR and 18F-FDG-PET/CT, the presence of vascular inflammation identified by 18F-FDG-PET/CT, and
the contribution by coronary artery disease shown by
CTCA. We investigated the relationship between imaging findings and biomarkers as well as any association
between pulmonary and cardiac pathology.

METHODS
Study Design and Population
The data that support the findings of this study are
available from the corresponding author upon reasonable request; however, any data that would allow possible identification of anonymized research patients will
not be made available.
Participants hospitalized with COVID-19 at the Aga
Khan University Hospital in Nairobi, Kenya, were recruited in this single-center exploratory observational
study (Figure 1). Inclusion criteria were patients aged
>18 years diagnosed with COVID-19 (positive on polymerase chain reaction testing) on presentation to
the hospital. The full study methodology with imaging techniques and protocols has been published.11
Briefly, participants were recruited on admission to
hospital. Following informed consent, blood draws
were taken. Patients then underwent multimodality
imaging as described in the Image Acquisition and
Assessment section. The study complies with the
Declaration of Helsinki with study approval from the
Aga Khan University Nairobi Institutional Ethics Review
Committee (reference: 2020/IERC-74 [v2]).
Exclusion criteria were contraindication to CMR,
known previous myocardial pathology, and those with
severe symptoms requiring noninvasive or invasive
ventilation. Patients underwent multimodality imaging
and serological testing (1 sample on admission) for
high-
sensitivity cardiac troponin I (hs-
cTnI; Siemens
Healthineers; normal, <2.5 pg/mL), NT-
proBNP (N-
terminal pro–brain natriuretic peptide; Siemens Atellica
Solution; normal, <300 pg/mL), CRP (C-reactive protein;
Siemens Atellica Solution; precision levels ≤0.3 mg/L),
and viral load12 (using cycle threshold; RealStar SARS-
CoV-
2 RT-
PCR Kit, Altona Diagnostics—
limit of detection at 625 copies/mL). We additionally identified a
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Figure 1. Study design.
Patients with acute COVID-19 were scanned on hospital admission. Cardiac magnetic resonance revealed myocarditis in 1 in 3
patients using the most stringest diagnostic criteria. Myocardial inflammatory cell infiltration identified by 2-deoxy-2-[fluorine-18]
fluoro-D -glucose PET/CT was present in 30% of all patients, and in the majority of patients with cardiac magnetic resonance–defined
myocarditis. No patient had significant coronary artery disease on CT coronary angiography scanning. No patient had vasculitis.
Although significant pulmonary inflammation and consolidation was common, it was not associated with the presence of myocarditis.
Troponin testing did not identify patients with imaging evidence of myocardial edema or inflammatory cell infiltration. CT indicates
computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography; and URL, upper reference limit.

small prospective control population of individuals who
had no symptoms and had COVID-
19 excluded by
polymerase chain reaction. This control group underwent the complete study protocol. In addition, for vascular analysis, we identified an age-and sex-matched
historical control population who had previously undergone 18F-FDG-PET/CT for another indication. This
historical control group had no other pathology, for example, had undergone 18F-FDG-PET/CT for follow-up
of a benign pulmonary nodule.

Image Acquisition and Assessment
Participants underwent simultaneous CTCA and thoracic 18F-FDG-PET/CT (GE Discovery MI series PET/CT
scanner) following admission, followed by CMR (Ingenia,
Philips Healthcare as described previously; Data S111).

Atherosclerotic Disease by CTCA
CTCA scanning was ECG gated and performed in
diastole during a single breath hold with prospective
ECG gating, detector collimation 64×0.625 mm, tube
voltage 120 kV, and window of acquisition 70% to 90%
(or wider if necessary because of heart rate). Tube
current varied depending on body mass index using
a prespecified manufacturer protocol. After the acquisition of scout images, CTCA was performed with
iodinated contrast (Ultravist 370 mg/mL) in a biphasic
injection protocol. Image acquisition was triggered
by contrast enhancement of 100 HU in the ascending aorta. Presence of coronary artery disease in each
major coronary artery and the main side branches
were classified as potentially obstructive (>50% stenosis) or nonobstructive.
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CMR was performed using a 3 Tesla system (Ingenia,
Philips Healthcare). Ejection fraction (EF) and regional
wall motion abnormalities (by cine balanced steady-
state free precession sequence), myocardial fibrosis,
edema, and presence of infarction in the left and right
ventricles by late gadolinium enhancement (LGE) were
determined as previously described (phase-sensitive
inversion recovery 5 minutes after administration of
0.1 mmol/kg gadolinium-based contrast agent).11 The
anatomical 17-segment model was used to derive T1,
T2, and extracellular volume values for each segment
excluding the apex.13 Before gadolinium administration, native T1 and T2 maps were acquired at the base,
mid-
ventricle, and apex. Postcontrast T1 mapping
was repeated in an identical manner to precontrast T1
mapping 12 minutes after gadolinium injection.
T1 mapping was acquired using a modified look
locker sequence using 10 images. Imaging parameters
were the following: field of view, 300 mm; slice thickness, 10 mm; flip angle, 20°; repetition time, 2.26 ms;
echo time, 1.03 ms; matrix, 256×256; 2.5 pixels/mm;
trigger delay end diastole; and inversion times ranging
from 137 to 5272 ms.
T2 mapping was performed using a multi-
echo
gradient-spin-echo sequence on the same ventricular
slices as T1 mapping. Repetition time was 1 RR interval. A total of 9 echoes were acquired using echo time
6 to 88 ms and echo train length 27. Slice thickness
was 10 mm; matrix, 300×300 pixels; 1.4 pixels/mm;
and field of view, 288×288 mm.

uptake was scored based on a visual scale. Patients
with focal or diffuse uptake were identified as having
acute myocardial inflammation.5
Semiquantative vascular inflammation on 18F-FDG-
PET/CT for the aorta was assessed by the American
Society of Nuclear Cardiologists visual grading criteria.15 Quantitative assessment was also undertaken
on large vessel inflammation.6 A maximum arterial
standardized uptake value was derived in serial axial
measurements across the ascending, arch, and descending aorta. The target-to-background ratio (TBR)
for each aortic region was calculated by averaging
the ratio of the maximum arterial standardized uptake
value to the mean venous standardized uptake value
for each segment. A total of 21 age-and sex-matched
historical controls who had previously undergone
clinical 18F-FDG-PET/CT scans for other indications
(eg, investigation of pulmonary nodules and reported
as normal) and 5 healthy active controls were also
scanned.
For pulmonary analysis, chest CT and 18F-FDG-
PET/CT images were analyzed separately for lung
consolidation and inflammation, respectively. The
3-dimensional lung contours were generated and linked
to the coregistered PET and CT images. Thresholds,
for pathology, were determined at 3 pooled SDs above
the population means. Control patients were used to
define thresholds to delineate consolidation on CT (by
lung density in Hounsfield units) and inflammation on
18F-FDG-PET (by standardized uptake value). The volumes of consolidated lung and inflamed lung were presented as percentages of total lung volume.

Myocardial, Vascular, and Pulmonary Pathology
by 18F-FDG-PET/CT

Statistical Analysis

We assessed myocardial inflammation as previously
described.5 Participants underwent imaging after a
high-fat, low-carbohydrate meal for 24 hours with an
18-
hour fast to reduce physiologic myocardial 18F-
FDG uptake.6,14 The PET imaging was performed 60 to
90 minutes after administration of 10 to 15 mCi of 18F-
FDG. The carotid arteries were the superior aspect of
imaging, and the entire thoracic aorta was covered
using 3-minute different bed positions with additional
dedicated 10-minute cardiac acquisition. CT images
were obtained immediately after PET scan acquisition.
A low-dose CT using 100 to 120 kVp and 30 to 50 mAs
(automatic exposure control system) was performed
immediately after the PET emission scan. Images were
reconstructed using ordered subset expectation maximization. The PET images were attenuation corrected
using the CT data and fused with CT for anatomical registration. CT and 18F-FDG-PET scan images
were coregistered, and analysis was performed using
the 17-
segment anatomical framework.13 Myocardial

Baseline clinical and imaging data were expressed as
the median (interquatile range) for continuous data and
categorical data as proportions. Clinical and imaging
data were presented by tertile of cardiac troponin (a
priori analysis), presence of myocarditis on CMR, myocardial cell infiltration on PET, and degree of pulmonary
inflammation/consolidation. A priori hypothesis testing
was carried out across categorical and continuous
covariates by tertile of cardiac troponin.11 Exploratory
hypothesis testing was further conducted when comparing clinical and imaging parameters by myocarditis
and myocardial cell infiltration status. A priori comparisons of covariate values by categories of troponin
levels were performed using the tableone package in
R (https://cran.r-project.org/web/packages/tableone/
vignettes/introduction.html). This included the Fisher
exact test for categorical variables and the Kruskal–
Wallis test for continuous variables. All other hypothesis
testing reported in the Results section was considered
exploratory. Hypothesis testing for troponin values by
cardiac pathology (presence of myocarditis on CMR or
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myocardial cell infiltration on cardiac PET) was done
on nontransformed data using a nonparametric test.
A P value of <0.05 was considered statistically significant. No correction for multiple testing was done.
Analysis was done in R (version 4.0.3; http://www.R-
project.org/).

RESULTS
Study Population
Of 64 consecutive patients with acute COVID-19, 33
were recruited (median age, 51 years [interquartile
range, IQR: 34–55], 31 [94%] men, and 31 (94%) Black
men from Kenya [Table 1, Table S1]). Of the patients, 13
declined to participate and 18 had exclusion criteria. A
total of 24 (73%) patients were hospitalized because
of respiratory symptoms of cough with or without
shortness of breath in the context of COVID-19. The
remaining patients had nonspecific viral symptoms
(fever, myalgia, arthralgia fatigue, diarrhea, nausea, or
vomiting). No patients had been vaccinated. A total of
29 patients underwent cardiac 18F-FDG-PET/CT, 26
Table 1. Baseline Characteristics of Patients With Acute
COVID-19 (N=33)

underwent CTCA, and 26 underwent CMR scanning
(Figure S1). CTCA and 18F-FDG-PET/CT scans were
performed at a median time of 4 days after presentation (IQR: 2–9 days). CMR scans were performed at a
median time of 10 days (IQR: 5–20 days). A total of 6
patients who were COVID-19 negative were recruited
as controls.
The prevalence of biochemical evidence of myocardial injury (hs-cTnI >99th centile upper reference limit)
was 5% (n=2/31). Tertiles of hs-cTnI levels only correlated with CRP (22 mg/L [IQR: 12–32] versus 85 [IQR:
50–100] versus 153 [IQR: 59–194]; P=0.001) (Table S2).
A total of 25 patients underwent assessment of viral
load by cycle threshold testing (7 high, 19 medium, 5
low) (Table S3). There was no association of viral load
by cycle threshold (25 [IQR: 25–28] versus 27 [IQR:
22–29]; P=0.57), CRP (34 mg/L [IQR: 13–75] versus
45 mg/L [IQR: 30–101]; P=0.47), NT-proBNP (35 pg/mL
[IQR: 9–252] versus 35 pg/mL [IQR: 28–58]; P=0.89),
or procalcitonin (0.04 ng/mL [IQR: 0.02–0.08] versus
0.11 ng/mL [IQR: 0.05–0.12]; P=0.17) levels comparing
patients with and without myocarditis. There was a
numerical but nonsignificant trend toward a lower duration of symptoms (6.5 days [IQR: 5-7] versus 4 days
[IQR: 3–7] versus 3 days [IQR: 2–5.5]; P=0.23) with increasing tertile of cardiac troponin.

Patients
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Demographics and past medical history
Age, y

51 [34–56]

Current/exsmokers

6 (18.2)

Diabetes

10 (31)

Hypertension

11 (33)

HIV

4 (13)

Clinical assessments
Symptom duration, days

4 [2–7]

Systolic BP, mm Hg

127 [120–136]

Diastolic BP, mm Hg

78 [70–85]

Heart rate, bpm

88 [80–92]

COVID-19 treatments
Oxygen requirement

19 (58)

Remdesevir

4 (13)

Dexamethasone

15 (47)

SARS-CoV-2 PCR (cycle threshold)

25 [20–29]

Laboratory measurements
Creatinine, μmol/L

97 [60–108]
9

White cell count, ×10 /L

6 [5–9]

D-dimer, mcg/mL

0.66 [0.37–1.09]

C-reactive protein, mg/L

55 [25–101]

Procalcitonin, ng/mL

0.07 [0.04–0.12]

NT-proBNP, pg/mL

35 [28–151]

Troponin, ng/L

3.88 [2.76–7.18]

Data are provided as number (percentage) or median [interquartile range].
BP indicates blood pressure; NT-proBNP, N-terminal pro–brain natriuretic
peptide; and PCR, polymerase chain reaction.

CMR Imaging
A total of 26 patients underwent CMR scanning. All
scans were of adequate quality for volume and wall
motion analysis. One scan was of insufficient quality for
T1-mapping analysis, 1 was of insufficient quality for T2
analysis, and 1 scan was inadequate for LGE analysis.
Myocarditis status was therefore available in 25 patients
using the specific 2018 Lake Louise Criteria.16
In the patient population, the median left ventricle
EF was 51% (IQR: 57–57), and right ventricle EF was
55% (IQR: 48–50). Median global native T1 was 1275
ms (IQR: 1250–1317), global extracellular volume was
25% (IQR: 24–28), and global T2 was 51 ms (IQR: 47–
54). A total of 9 patients (35%, n=9/25) had LGE. Of
these, 2 (22%) had subendocardial LGE, and 8 (89%)
had mid-wall or epicardial LGE. Of the 9 patients with
LGE, 7 (78%) also had evidence of active myocardial
edema by T2 value.
A total of 9 (35%, n=9/25) patients had evidence
of active myocarditis by the most specific 2018 Lake
Louise criteria (Table 2, Figure 2). Of these patients, 6
(67%, n=6/9) had evidence of LGE, with 4 in a myocarditis pattern (mid-wall), 1 with subendocardial LGE,
and 1 with both. A total of 13 patients (50%, n=13/25)
had evidence of myocarditis by the sensitive criteria
(Table S4).
Cardiac troponin concentrations were numerically
higher in patients with myocarditis compared with
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Table 2. CMR Imaging Results Stratified by the Specific 2018 Lake Louis II Diagnosis of Myocarditis: Cardiac
18F-FDG-PET/CT Evidence of Myocardial Inflammatory Cell Infiltration
Patients

Myocarditis
(CMR)

No myocarditis
(CMR)

Inflammatory cell
infiltration (cardiac PET)

No inflammatory cell
infiltration (cardiac PET)

No.

26*

9

16

7

16

LV ejection fraction, %

61 [57–67]

59 [56–62]

64 [59– 68]

62 [60–63]

60 [56–69]

LV EDVi, mL/m2

65 [62–72]

65 [60–73]

66 [62–72]

64 [56–75]

66 [62–72]

2

26 [21–30]

25 [21–29]

25 [21–32]

22 [21–27]

2 [20–32]

LV SVi, mL/m2

42 [34–48]

38 [30–44]

44 [38–49]

38 [31–42]

44 [36–50]

RV ejection fraction, %

56 [48–60]

50 [47– 58]

58 [54–60]

52 [48–56]

59 [52– 61]

T1–maximum, ms

1356 [1304–1412]

1342 [1301–1403]

1372 [1322–1414]

1317 [1297–1405]

1380 [1335–1424]

LV ESVi, mL/m

T2–maximum, ms

62 [57–68]

68 [67–70]

58 [56–62]

66 [64–69]

60 [56–63]

ECV, maximum %

31 [28–34]

34 [31–36]

29 [27–32]

33 [31–35]

30 [27–34]

LGE, %

9 (35)

6 (67)

2 (12)

6 (86)

3 (19)

Subendocardial LGE, %

2 (8)

2 (22)

0 (0)

2 (29)

0 (0)

5 (56)

2 (12)

5 (71)

3 (19)

5 (71)

3 (20)

Mid-wall, %

8 (31)

Myocarditis-specific Lake
Louis criteria, CMR

9 (36)

Myocardial inflammatory
cell infiltration, PET

7 (30)

5 (63)

2 (14)

Pulmonary inflammation,
percentage of lung

17 [3–29]

16 [2–30]

17 [10–31]

7 [2–20]

22 [13–38]

Pulmonary consolidation,
percentage of lung

12 [7–18]

10 [8–16]

13 [7–18]

9 [8–12]

16 [7–19]
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Data are provided as number, number (percentage), or median [interquartile range]. 18F-FDG indicates 2-deoxy-2-[fluorine-18]fluoro-D-glucose; CMR,
cardiac magnetic resonance; CT, computed tomography; ECV, extracellular volume; EDVi, indexed end-diastolic volume; ESVi, indexed end-systolic volume;
LGE, late gadolinium enhancement; LV, left ventricle; PET, positron emission tomography; RV, right ventricle; SVi, systolic volume indexed; T1, longitudinal
relaxation time; and T2, horizontal relaxation time.
*Denominators differ for each modality because not all scans were performed/diagnostic on every patient.

those without (8.4 [IQR: 4.0–
55.3] versus 3.5 [IQR:
2.5–5.5]; P=0.07) (Table S5). No differences in viral
load (25 [IQR: 20–28] versus 27 [IQR: 22–29]; P=0.70),
left ventricle diastolic volume (55 mL/m2 [IQR: 50–73]
versus 55 [IQR: 52–72]; P=0.84), or left ventricle EF
(59% [IQR: 55–52] versus 54 [IQR: 59–58]; P=0.23)
were found in patients with and without myocarditis
(Table 1, Table S1, and Table S2).

Computed Tomography Coronary
Angiography
A total of 25 patients underwent CTCA, and all had
sufficient image quality. No patients had significant
obstructive coronary artery disease (lumen stenosis>50%; Figure 3).

Positron Emission Tomography/Computed
Tomography
Vascular Inflammation
Arterial inflammation in the ascending aorta by TBR
was 1.97±0.35 (Figure S2 and Table S6) and similar to
historical or active controls (1.92±0.32 and 2.03±0.05;
P=0.74). There was no significant regional variation in

TBR values in different aortic segments (Table S7). No
patients fulfilled the visual criteria for inflammation in the
aorta or carotids (Figure S3). There was no correlation
with aortic fluorodeoxyglucose uptake (TBR) and CRP,
hs-cTnI, or viral load (Table S8). Ascending aorta TBR
was similar in patients with and without CMR myocarditis (1.93±0.18 versus 2.00±0.44; P=0.55) and with
and without myocardial inflammatory cell infiltration on
18F-FDG-PET (1.97±0.17 versus 1.91±0.21; P=0.47).
Myocardial Inflammatory Cell Infiltration
A total of 2 patients were not adequately fasted for
cardiac analysis. Of the remaining patients, 8 (30%,
n=8/27) had evidence of myocardial inflammatory
cell infiltration. Of these patients, 3 had focal uptake
(Figure 3), 4 had focal on diffuse (Figure 4), and 1 had
diffuse (Figure 2).
A total of 22 patients had both CMR and 18F-FDG-
PET/CT. Of these, 8 patients had CMR-defined myocarditis by using the specific 2018 Lake Louise criteria,
and 5/8 (53%) also had simultaneous evidence of inflammatory cell infiltration. Similarly, of the 8 patients
who had evidence of inflammatory cell infiltration by
18F-FDG-PET/CT, 5/8 (53%) had myocardial edema
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Figure 2. Severe myocarditis with minimal lung injury.
There is mid-wall injury at the basal myocardium in the septum (white arrows) shown by cardiac magnetic resonance (CMR) (A) native
T1, (B) postcontrast T1, and late gadolinium enhancement (H; blue arrow). There is no increase in T2 values in this basal region (C), but
there is gross increase in mid-ventricular septal T2 (D; red arrows), indicating edema remote to prior myocardial fibrosis. There was
minimal lung consolidation (E; red contours) or inflammation (F; blue contours). There is diffuse biventricular 2-deoxy-2-[fluorine-18]
fluoro-D -glucose uptake (significantly higher than in the liver) (G). The patient had severe left and right ventricle impairment with
elevated high-sensitivity cardiac troponin I (110 ng/L) and NT-proBNP (N-terminal pro–brain natriuretic peptide; 7140 pg/mL) but low
CRP (C-reactive protein; 10 mg/L).
Downloaded from http://ahajournals.org by on October 5, 2022

on CMR. A total of 12 patients (55%, n=12/22) had no
evidence of myocarditis or cellular uptake on CMR or
18F-FDG-PET/CT.
Pulmonary Injury
Of the patients, 29 with acute COVID-19 infection and
5 controls underwent pulmonary 18F-
FDG-
PET/CT.
Overall, 25 patients had both CMR and pulmonary
18F-FDG-PET/CT performed.
In patients with acute COVID-
19, the median
amount of inflammation (based on 18F-FDG-PET) and
consolidation (based on CT) as a percentage of total
lung volume was 17% (IQR: 5%–31%) and 11% (IQR:
7%–18%), respectively. In controls, there was 0.18%
(IQR: 0.15%–
0.57%) inflammation and 3.0% (IQR:
2.7%–3.1%) consolidation.
When categorizing patients who underwent both
CMR and pulmonary 18F-FDG-PET/CT into tertiles, 7
of 25 patients had 0% to 5%, 9 of 25 had 5% to 25%,
and 9 of 25 had >25% inflammation of the total lung
volume (Table S7). Similarly, 5 of 25 patients had 0% to
7%, 10 of 25 had 7% to 15%, and 10 of 25 had >15%
consolidation of total lung volume (Table S9).
The degree of lung inflammation (15% [IQR:
2%–
30%] versus 17% [IQR: 10%–
31%]; P=0.95) or

consolidation (10% [IQR: 8%–15%] versus 13% [IQR:
7%–18%]; P=0.85) was comparable in patients with
and without myocarditis (Figure 4). Similarly, the degree of lung inflammation (7% [IQR: 2%–20%] versus
22% [IQR: 13%–38%]; P=0.11) or consolidation (9%
[IQR: 8%–12%] versus 15% [IQR: 7%–19%]; P=0.23)
was comparable in patients with and without myocardial inflammatory cell infiltration.
There was no association between the presence
of myocarditis and the degree of lung injury. Of patients with CMR-based myocarditis, 3 of 9 (37.5%) had
severe pulmonary inflammation compared with 5 of
17 (35.3%) without myocarditis (P=1.0). Patients with
myocardial inflammatory cell infiltration, compared
with those without, had numerically lower pulmonary
inflammatory involvement (5% [IQR: 2%–17%] versus
24% [IQR: 13%–38%]; P=0.05). There was no correlation between severity of lung inflammation (55% [IQR:
52%–50%] versus 54% [IQR: 45%–59%]; P=0.57) or
consolidation (57% [IQR: 51%–50%] versus 54% [IQR:
49%–59%]; P=0.52) with right ventricle EF. Similarly, no
correlation was seen for severity of lung inflammation
(81 ms/m2 [IQR: 71–85] versus 71 [55–79]; P=0.35) or
consolidation (79 ms/m2 [IQR: 70–85] versus 74 [IQR:
55–82]; P=0.52) with indexed right ventricle diastolic
volumes (Table 3).
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Figure 3. Focal inferolateral myocarditis with no atherosclerotic disease.
Changes (white arrows) in the native and postcontrast cardiac magnetic resonance (CMR) T1 values (A and B), 2-deoxy-2-[fluorine-18]
fluoro-D -glucose positron emission tomography focal uptake (C), and subendocardial fibrosis on CMR late gadolinium enhancement
(D). There was no significant coronary artery disease on computed tomography coronary angiography (E through G). Biochemical
cardiac and inflammatory markers were low (high-sensitivity cardiac troponin I, 2.72 ng/L; NT-proBNP [N-terminal pro–brain natriuretic
peptide], <35 pg/mL; CRP [C-reactive protein], 4 mg/L). Cx indicates left circumflex coronary artery; LAD, left anterior descending
coronary artery; and RCA, right coronary artery.
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DISCUSSION
To our knowledge, this is the first study to systematically use molecular imaging alongside anatomical and
functional modalities to explore cardiovascular and
pulmonary pathobiology in acute COVID-19 infection.
We make some important observations. First, rates of
myocarditis (by CMR criteria) and myocardial inflammatory cell infiltration (by 18F-FDG-PET/CT imaging) were
significant at 35% and 30%, respectively. Second, the
median burden of lung inflammation and consolidation
was quantified at 17% and 11% of total lung volume,
respectively. Lung involvement, both inflammation and
consolidation, did not correlate with the presence of
myocarditis or myocardial inflammatory cell infiltration.
Third, vasculitis was not present in acute COVID-19.
Finally, biochemical evidence of myocardial injury was
not common with only 2 patients with acute COVID-19
showing elevated troponin levels.
Our rates of myocarditis, despite recruiting patients
with acute COVID-19, were lower than previously reported1 but similar to other recent studies.2,3 This in
part reflects our choice of using the more specific 2018
Lake Louise criteria to define CMR-based myocarditis. Indeed, the prevalence of myocarditis rose from 1
in 3 to 1 in 2 when applying the most sensitive criteria as in previous studies.1 Using 18F-FDG-PET/CT
imaging, myocardial inflammatory cell infiltration was

present in 1 in 3 cases. Surprisingly, neither the presence of myocarditis nor myocardial cell infiltration was
associated with biochemical evidence of cardiac injury. Myocarditis may not always result in cell necrosis
and troponin release.17,18 Furthermore, troponin release
may be dynamic19,20 and may not be appreciated on
single-
point blood sampling on hospital admission.
Alternatively, troponin release may occur weeks after
initial presentation with myocarditis.19,20 Finally, studies on myocarditis have generally been restricted to
patients with troponin elevations in whom significant
coronary disease has been excluded.21 In contrast,
our study involved cardiac imaging of an unselected
population with an acute viral infection, regardless of
troponin concentration.
Although CMR-
based tissue characterization
can indicate myocardial edema, molecular imaging
with 18F-
FDG-
PET/CT reflects myocardial cellular
infiltration—a better indicator of an acute inflammatory process.22,23 Of those patients who had CMR-
defined myocarditis, only 53% had an inflammatory
cell presence. This suggests that acute myocardial
inflammation may have either occurred before presentation or edema is not always attributed to direct
cellular infiltration. SARS-CoV-2 infection is present in
the myocardium in the majority of individuals dying
from COVID-19.23 Furthermore, in vitro studies have
shown SARS-CoV-2 cytopathic infection of cardiac
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Figure 4. Cardiac and pulmonary 2-deoxy-2-[fluorine-18]fluoro-D -glucose positron emission tomography/CT imaging in 2
patients showing discordance between pulmonary and myocardial involvement.
Top panel (blue outline) represents a patient with significant myocardial inflammatory cell infiltration with some pulmonary
involvement—17% lung consolidation and 29% inflammation. Cardiac inflammatory cell infiltration (focal on diffuse bright spots in
lateral anterior and septal walls). Bottom panel (red outline) represents another patient with no myocardial involvement but with
significant lung consolidation (35%) and inflammation (54%). Lung consolidation on computed tomography (CT; A and D; red contours)
and lung inflammation (B and E; blue contours) are shown. Green contours indicate lung parenchyma. Fused image (C and F) showing
lung inflammation with heat maps on CT. Cardiac 2-deoxy-2-[fluorine-18]fluoro-D -glucose positron emission tomography shows
inflammatory cell infiltration in the short axis (i and iv), 2-chamber (ii and v), and 4-chamber views (iii and vi).

myocytes with macrophage and lymphocytic infiltration.1,23,24 However, a cytokine storm has also been
implicated in COVID-
19 infection.25,26 This process
occurs sometime after viral inoculation and may also
result in cardiac pathology without the presence of
SARS-CoV-2 in the myocardium.27 In this case, systemic cytokines may also cause systemic capillary
leak (with resultant edema) without cellular infiltration
of all tissues.28 Therefore, cardiac injury may result
from a dual-injury process: initially from viral infection
followed by a subsequent cardiac insult from a systemic inflammatory response. In keeping with this,
we demonstrated that some patients had evidence
of prior myocardial fibrosis without associated edema
but then also had active edema without fibrosis in
other regions (Figure 2).
Although the pathogenesis of hypercoagulability in
COVID-19 remains unclear, vascular thrombosis has
been described in hospitalized patients.29 Endothelial
injury and vascular inflammation have been postulated
to play a central role.30,31 In contrast, our study did not

find any supporting evidence of arterial inflammation in
acute COVID-19. We further found no evidence of coronary thrombosis to explain the myocardial pathology
observed (Figure 3). A previous study demonstrated
coronary artery obstruction and ischemic injury patterns on CMR; however, the study population was restricted to those with troponin elevations.3 As such, we
can conclude that the mechanism of cardiac pathology
in acute COVID-19 is unlikely to have occurred secondary to coronary atherosclerosis, and the reported high
prevalence of vascular thrombosis is not attributed to
an arterial vasculitic process.29
Macrophages and monocytes are known to be involved in the pathogenesis of acute respiratory distress
syndrome, and there is growing evidence of their involvement in COVID-19–related pulmonary injury.32 We
showed that the degree of pneumonitis, by 18F-FDG-
PET/CT, was variable, correlated with the degree of
lung consolidation but was not associated with presence of myocarditis. This suggests that myocarditis
can occur in patients with minimal lung involvement.
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Table 3. CMR Imaging Results Stratified by 18F-FDG-PET/CT Evidence of Pulmonary Inflammation or Consolidation
Patients

<25% Pulmonary
inflammation (PET)

≥25% Pulmonary
inflammation (PET)

<15% Pulmonary
consolidation (CT)

≥15% Pulmonary
consolidation (CT)

No.

26*

9

16

10

15

LV ejection fraction, %

61 [57–67]

57 [55–62]

64 [60– 68]

58 [54–64]

64 [60– 68]

LV EDVi, mL/m2

65 [62–72]

66 [60–73]

65 [64–72]

64 [60–72]

65 [64–76]

LV ESVi, mL/m2

25 [21–29]

26 [21–32]

22 [21–27]

26 [22–30]

22 [20–28]

LV SVi, mL/m2

42 [34–48]

41 [32– 46]

44 [37–49]

38 [32– 48]

44 [38–48]

RV ejection fraction, %

56 [48–60]

54 [45–59]

56 [52–60]

54 [49–59]

57 [51–60]

T1–maximum, ms

1356 [1304–1412]

1407 [1369–1415]

1321 [1298–1400]

1376 [1337–1412]

1334 [1299–1424]

T2–maximum, ms

62 [57–68]

62 [57–67]

62 [56–67]

60 [57–67]

62 [58–67]

ECV, maximum %

31 [28–34]

32 [26–34]

30 [29–34]

30 [26–34]

31 [29–35]

LGE, %

9 (35)

3 (33)

6 (38)

4 (40)

5 (33)

Subendocardial LGE, %

2 (8)

0 (0)

2 (12)

0 (0)

2 (13)

Mid-wall LGE, %

8 (31)

3 (33)

5 (31)

4 (40)

4 (27)

Myocarditis-specific Lake
Louis criteria, CMR

9 (36)

3 (33)

5 (33)

3 (33)

5 (33)

Myocardial inflammatory
cell infiltration, PET

7 (30)

1 (11)

6 (43)

1 (11)

6 (43)

Pulmonary inflammation,
percentage of lung

17 [3–29]

38 [29–42]

10 [1–17]

35 [29–41]

7 [1–15]

Pulmonary consolidation,
percentage of lung

12 [7–18]

18 [17–26]

8 [6–13]

18 [18–25]

8 [5–11]

Data are provided as number, number (percentage), or median [interquartile range]. 18F-FDG indicates 2-deoxy-2-[fluorine-18]fluoro-D-glucose; CMR,
cardiac magnetic resonance; CT, computed tomography; ECV, extracellular volume; EDVi, end-diastolic volume indexed; ESVi, end-systolic volume indexed;
IQR, interquartile range; LGE, late gadolinium enhancement; LV, left ventricle; PET, positron emission tomography; RV, right ventricle; SVi, systolic volume
indexed; T1, longitudinal relaxation time; and T2, horizontal relaxation time.
*Denominators differ for each modality because not all scans were performed/diagnostic on every patient.
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Our study has some limitations. First, although
achieving comprehensive phenotyping, this was an
observational study in a small COVID-19 population.
Almost half of the patients received either dexamethasone or remdesivir, which may have supressed the
inflammatory response and underestimated myocardial inflammation. Scanning, however, was performed
early in the clinical course. Second, our assessment
of vasculitis was based on 18F-FDG-PET/CT uptake
in the large vessels. Vascular inflammation in the
smaller vessels, because of limited spatial resolution,
may be undetected. However, if vascular inflammation was secondary to a systemic cytokine storm or
immune response, it would have been expected that
this would have been reflected in the aorta and the
medium-sized carotids. Third, we excluded patients
with severe COVID-19 who were unable to tolerate
imaging, limiting the generalizability of our findings
in this population. Finally, we did not perform cardiac biopsy. Although this is the gold standard for the
diagnosis of myocarditis, we performed deep phenotyping using 3 different imaging modalities. The
combination of myocardial inflammatory cell identification by 18F-FDG-PET and myocarditis detection
by CMR (using the strictest criteria) make our findings
robust.

In conclusion, with the use of multimodality imaging in acute COVID-19 infection we make several observations. Myocarditis was present in 1 in 3 patients,
and the majority of these patients had evidence of inflammatory cell infiltration by cardiac 18F-FDG-PET/
CT. Pneumonitis was ubiquitous in acute COVID-19,
but this inflammation was not associated with CMR
myocarditis. The mechanism of cardiac pathology in
acute COVID-19 is nonischemic, and vascular thrombosis in acute COVID-19 is not attributable to a vasculitic process that involves large-or medium-sized
vessels.
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Data S1.

Supplemental Methods

SCAN ANALYSIS

CMR
CMR: CMR scans were analysed using dedicated software (Circle Cardiovascular Imaging
Inc., Calgary, Canada). Control studies (5 participants; 80 segments) were used to determine
T1, T2 and ECV cut-off values. In the controls, the mean LV EF was 62 ± 5 % and RV EF 61
± 7 %. The median native T1, ECV and T2 across the segments was 1247ms (IQR 12251281), 27% (IQR 25-29) and 47ms (IQR 44-51) respectively. The 97.5 percentile used to
identify abnormal segments on patient scans were 1384 ms for T1 and 64 ms for T2
relaxation times, and 31% for the ECV. No controls had subendocardial LGE and 1 had midwall LGE. The derived cut off values
For comparison, values over the 97.5 percentile of published normal values for T1 (1236 ms),
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T2 (64 ms) relaxation times and ECV (33%) for 3T CMR scanning were used (33).
The myocardium was separated into 16 segments of the American Heart Association 17segment model excluding the apex (34). Manual endocardial and epicardial contours were
drawn, and the segmentation was automated after identification of the superior RV insertion
point. To ensure the blood pool or extra cardiac structures were excluded and only
myocardium sampled, a 15% off-set was applied to both contours. T1 values ,T2 values, extra
cellular volume and the presence of late gadolinium enhancement (LGE) were generated for
each segment using dedicated software (Circle CVI) (35). T1 values indicated fibrosis or
oedema, T2 values indicated oedema and gadolinium enhancement indicated the presence of
infarction or fibrosis depending on distribution (36-39).
Quantitative blinded analysis was performed by a trained consultant cardiologist with
expertise in CMR (Manchester, UK).

PET
Vascular
18F-FDG-PET/CT scans were analysed using dedicated software (OsiriX 64-bit; OsiriX
Imaging Software, Geneva, Switzerland). Semi qualitative vascular inflammation was
assessed by the American Society of Nuclear Cardiologists visual grading criteria as follows:
Grade 0 - No vascular uptake (≤ mediastinum), Grade 1: Vascular uptake < liver uptake,
Grade 2: Vascular uptake = liver uptake, may be PET-positive, Grade 3: Vascular uptake >
liver uptake, considered PET-positive (40). Vascular inflammation was determined to be
present in patients with Grade 2 or Grade 3 uptake.
Quantitative assessment was also undertaken large vessel inflammation (6,41). In brief,
regions of interest were drawn around the aorta in the axial position, repeated along the
length of the aorta. A mean arterial SUV was derived from the average of the maximum SUV
values in serial axial measurements across the whole aorta and in aortic segments (ascending,
arch and the descending aorta). Similarly the average of mean SUV measurements from the
venous pool derived the mean venous background SUV. The target-to-background (TBR)
ratio was then calculated by dividing the maximum arterial SUV by the mean venous SUV.
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Twenty-one age and sex matched patients who had previously undergone clinical 18F-FDGPET/CT scans and reported as normal (eg. investigation of pulmonary nodules) were used as
historical controls. Five patients were also scanned as active controls.
Blinded analysis was performed by a trained consultant cardiologist with expertise in
vascular PET scanning (Bristol, UK).

Cardiac
Standardised methodology for assessing myocardial inflammation PET/CT remains less well
established. Myocardial uptake, on adequately fasted patients, was scored based on a visual
scale and categorised as (i) none, (ii) focal uptake, (iii) focal on diffuse uptake, (iv) diffuse
uptake (with uptake greater than the liver) or (v) non diagnostic (generalised uptake equal to
or higherthan the liver). Liver SUV uptake was measured by drawing a hepatic region of
interest. Patients with focal or diffuse uptake were identified as having acute myocardial
inflammation. Visual uptake in the lateral myocardial wall was only identified as acute
myocardial inflammation if uptake was >1.5 fold higher than in the septal or anterior walls

(42,43). Semi-qualitative blinded was performed by 2 consultant cardiologists and verified
independently by a consultant cardio-thoracic radiologist specialised in nuclear radiology
(Edinburgh & Manchester, UK and Nairobi, Kenya). Patients filled in a questionnaire before
PET scanning, and were excluded from myocardial analysis if the fasting protocol was not
adhered to.

Pulmonary
Chest CT and 18F-FDG-PET/CT images from hybrid scanner acquisitions were viewed
and analyzed using MIM 7.1.2TM (MIM Software, Cleveland, OH). Three
dimensional lung contours were first generated on CT using an automated densitybased region-growing segmentation tool. Preliminary total lung contours were
manually refined on each transaxial slice with a brush tool to include all well-aerated and
consolidated lung tissue, while excluding proximal bronchovascular structures as well
as mediastinal and hilar lymph nodes. Refined total lung contours were linked to the coregistered PET and CT images of all patients. In the control patient cohort, summary
statistics of refined total lung contours (population mean, pooled standard deviation) were
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computed to define variation in CT-based normal lung density (in Hounsfield units [HU]) and
PET-based physiologic background FDG uptake (in standardized uptake value [SUV]). Based
on the control group summary statistics, thresholds to delineate consolidation on CT and
inflammation on FDG-PET were set as 3 pooled standard deviations above the population
mean HU and SUV, respectively. Within the refined total lung contours of the COVID-19
positive patient cohort, regions above the control group thresholds (-310 HU, 1.8
SUV) defined consolidated lung on CT and inflamed lung on FDG-PET. The volumes
(absolute, relative fraction) of consolidated lung and inflamed lung were calculated. Examples
of refined total lung, consolidated lung, and inflamed lung contours are shown in Figure 3.
Blinded analysis was performed by a trained nuclear radiologists with expertise in pulmonary
PET scanning (Washington, USA).

CMR
Myocarditis
(specific 2018
Lake Louis
criteria)

CMR No
Myocarditis
(specific 2018
Lake Louis
criteria)

Inflammatory
cell infiltration
(Cardiac PET)

No Inflammatory
cell infiltration
(Cardiac PET)

Severe
pulmonary
inflammation
(Lung PET)

Non-severe
pulmonary
inflammation
(Lung PET)

Severe
Pulmonary
Consolidation

Non-Severe
Pulmonary
Consolidation

9

17

8

19

11

18

11

18

51 [49, 59]

48 [33, 52]

50 [47, 54]

51 [34, 57]

52 [40, 59]

50 [38, 54]

52 [33, 59]

51 [43, 56]

Current or Ex-smokers
(%)
Diabetes (%)

2 ( 22)

3 (18)

1 ( 12)

5 ( 26)

3 (27)

3 (17)

2 (18)

4 (22)

4 ( 50)

3 ( 18)

3 ( 43)

5 ( 26)

3 ( 27)

5 ( 29)

2 ( 18)

6 ( 35)

Hypertension (%)

4 ( 44)

4 ( 24)

2 ( 25)

7 ( 37)

3 ( 27.3)

7 ( 38.9)

3 ( 27)

7 ( 39)

n
Age, years (median [IQR])
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HIV (%)

2 ( 29)

1 ( 6)

1 ( 17)

0 ( 0)

0 ( 0.0)

2 ( 13)

0 ( 0.0)

2 ( 13)

Symptoms duration, days
(median [IQR])

5 [4, 7]

4 [3, 7]

5 [4, 6]

3 [2, 7]

4 [3, 8]

3.50 [2, 7]

7 [4, 8]

3 [2, 5]

Systolic BP, mmHg
(median [IQR])

133 [125, 138]

120 [120, 133]

138 [124, 145]

127 [115, 133]

133 [119, 136]

123 [120, 137]

129 [124, 134]

123 [120, 141]

Diastolic BP, mmHg
(median [IQR])

84 [81, 86]

74 [70, 78]

84 [80, 87]

75 [70, 80]

75 [72, 80]

79 [70, 86]

74 [70, 80]

79 [71, 86]

Heart rate, bpm (median
[IQR])

86 [80, 90]

90 [86, 100]

88 [81, 93]

88 [79, 90]

89 [79, 93]

87 [81, 92]

90 [84, 103]

86 [80, 90]

O2 requirement (%)

6 ( 67)

9 ( 52.9)

4 ( 50)

11 ( 58)

10 ( 91)

7 ( 39)

9 ( 82)

8 ( 44)

Remdesevir (%)

1 ( 11)

2 ( 13)

0 ( 0)

4 ( 22)

4 ( 36)

0 ( 0.0)

4 ( 36)

0 ( 0.0)

Dexamethasone (%)

3 ( 33)

9 ( 56)

2 ( 25)

10 ( 56)

7 ( 64)

7 ( 41)

8 ( 73)

6 ( 35)

26 [20, 28]

27 [22, 29]

26 [22, 27]

25 [20, 29]

23 [22, 29]

27 [20, 29]

26 [22, 29]

26 [18, 29]

101 [82, 109]

91 [79, 106]

100 [83, 114]

91 [78, 106]

99 [78, 109]

98 [82, 107]

101 [78, 107]

94 [80, 110]

6 [4, 7]

6 [5, 9]

6 [4, 9]

6 [5, 8]

7 [5, 9]

6 [4, 8.]

6 [4, 8]

6 [5, 10]

0.21 [0.20, 0.52]

0.88 [0.64, 1.32]

0.58 [0.27, 2.42]

0.84 [0.51, 1.29]

0.88 [0.61, 1.39]

0.70 [0.36, 0.94]

0.66 [0.51, 0.88]

0.83 [0.47, 1.31]

34 [13, 75]

68 [31, 101]

16 [8, 43]

96 [42, 148]

124 [67, 153]

42 [20, 82]

101 [68, 151]

36 [17, 82]

0.04 [0.02, 0.09]

0.10 [0.05, 0.12]

0.04 [0.03, 0.04]

0.08 [0.05, 0.118]

0.11 [0.05, 0.13]

0.05 [0.04, 0.08]

0.11 [0.08, 0.13]

0.04 [0.04, 0.07]

35 [9, 252]

35 [28, 63]

35 [28, 111]

44 [32, 162]

63 [25, 163]

35 [35, 151]

63 [31, 182]

35 [35, 126]

8.41 [4.01, 55.35]

3.51 [2.50, 5.58]

4.44 [3.43, 8.34]

3.62 [2.99, 7.19]

5.58 [2.99, 8.41]

3.62 [2.72, 6.89]

4.60 [2.99, 6.88]

4.14 [2.72, 7.20]

SARS-CoV-2 PCR (cycle
threshold) (median [IQR])
Creatinine, μmol/l (median
[IQR])
White cell count x109/L
(median [IQR])
D-dimer mcg/ml (median
[IQR])
C-reactive protein, mg/l
(median [IQR])
Procalcitonin, ng/ml
(median [IQR])
NT pro-BNP, pg/ml
(median [IQR])
Troponin, ng/L (median
[IQR])

Table S1: Baseline characteristics of patients with acute COVID-19 stratified by CMR-defined myocarditis, cardiac 18F-FDG-PET/CT evidence of
myocardial inflammatory cell infiltration and presence of pulmonary inflammation or consolidation.

Troponin by high sensitivity assay
Tertile

1

2

3

[2.50, 2.77)

[2.77, 6.59)

[6.59,2637.03]

8

13

11

46.50 [32.75, 51]

49 [33, 52]

56 [51, 59]

0.05

7 ( 87.5)

13 (100.0)

10 ( 90.9)

0.50

0 (0)

2 (15.4)

3 (27.3)

0.32

Diabetes (%)

3 ( 42.9)

3 ( 23.1)

3 ( 27.3)

0.78

Hypertension (%)

1 ( 12.5)

3 ( 23.1)

7 ( 63.6)

0.05

Value (pg/L)
n
Age, years (median [IQR])
Sex, male (%)
Current / Exsmoker (%)

p

Symptoms duration - days (median
[IQR])
Systolic BP, mmHg (median [IQR])

6.50 [5, 7]

4 [3, 7]

3 [2, 5.50]

0.23

120 [117.50, 123.75]

129 [120, 135]

133 [115, 138]

0.36

Diastolic BP, mmHg (median [IQR])

76.50 [70, 83.25]

79 [75, 88]

70 [70, 84.50]

0.59

89 [87, 94]

89 [81, 95]

81 [79, 88]

0.47

Oxygen requirement (%)

3 ( 37.5)

6 ( 46.2)

9 ( 81.8)

0.11

Remdesevir (%)

0 ( 0.0)

3 ( 25.0)

1 ( 9.1)

0.41

Dexamethasone (%)

2 ( 25.0)

6 ( 50.0)

7 ( 63.6)

0.28

14.96 [13.58, 26.12]

27.94 [23.20, 29.23]

24.40 [20.90, 30.38]

0.09

84 [74.50, 107.50]

96 [79, 106.25]

101 [92, 115]

0.38

White cell count x10^9 (median [IQR])

5.48 [3.90, 7.43]

5.77 [5.17, 8.60]

6.79 [5.27, 9.25]

0.52

Lymphocyte count x10^9 (median [IQR])

1.51 [1.22, 1.72]

1.45 [1.23, 1.85]

1.28 [1.00, 1.71]

0.79

D-dimer mcg/ml (median [IQR])

0.93 [0.43, 1.56]

0.65 [0.46, 0.80]

0.74 [0.22, 1.04]

0.87

22 [12, 32]

86 [50, 100]

153 [59, 194]

0.001

Procalcitonin, ng/ml (median [IQR])

0.03 [0.01, 0.06]

0.08 [0.04, 0.12]

0.08 [0.05, 0.17]

0.124

NT pro-BNP, pg/ml (median [IQR])

35 [20.49, 39.25]

35 [28.12, 56.52]

151 [58, 388.30]

0.05

Inflammation, % of lungs (median [IQR])

15 [9, 22]

22 [15, 38]

21 [2, 32]

0.55

Consolidation, % of lungs(median [IQR])

13 [9, 15]

14 [7, 19]

11 [8, 18]

0.97

Myocarditis (MRI), %

2 ( 28.6)

1 ( 11.1)

5 ( 55.6)

0.17

Myocardial inflammatory cell infiltration
(PET), %

2 ( 33.3)

3 ( 25.0)

2 ( 20.0)

0.72

Heart rate, bpm (median [IQR])

SARS-CoV-2 PCR (cycle threshold)
(median [IQR])
Creatinine, μmol/l (median [IQR])
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C-reactive protein, mg/L (median [IQR])

Table S2: Baseline characteristics stratified by troponin concentration.

Viral load
n
Age, years (median [IQR])
Sex, male (%)
Current / Exsmoker (%)
Diabetes (%)
Hypertension (%)
Symptoms duration - days (median [IQR])
Systolic BP, mmHg (median [IQR])
Diastolic BP, mmHg (median [IQR])
Heart rate, bpm (median [IQR])
Oxygen requirement (%)
Remdesevir (%)
Dexamethasone (%)
SARS-CoV-2 PCR (cycle threshold) (median [IQR])
Creatinine, μmol/l (median [IQR])
White cell count x10^9 (median [IQR])
Lymphocyte count x10^9 (median [IQR])
D-dimer mcg/ml (median [IQR])
C-reactive protein, mg/l (median [IQR])
Procalcitonin, ng/ml (median [IQR])
NT pro-BNP, pg/ml (median [IQR])
Troponin, ng/L (median [IQR])
Inflammation, % of lungs (median [IQR])
Consolidation, % of lungs(median [IQR])
Myocarditis (MRI)
Myocardial inflammatory cell infiltration (PET)

High
7
51 [46.50, 53.50]
6 ( 85.7)
1 (14.6)
5 ( 83.3)
3 ( 42.9)
5 [3, 7]
121 [120, 137]
81 [78, 89]
88 [81, 89]
1 ( 14.3)
0 ( 0.0)
1 ( 14.3)
14.35 [13.55, 15.87]
88 [71, 114.50]
5.77 [4.73, 7.61]
1.65 [1.38, 1.78]
0.67 [0.24, 1.17]
25 [9, 55.50]
0.06 [0.02, 0.07]
35 [22.20, 43.50]
2.50 [2.50, 4.07]
0.15 [0.07, 0.17]
0.09 [0.07, 0.10]
2 ( 50.0)
1 ( 20.0)

Viral Load by Cycle Threshold
Medium
Low
19
5
51 [37.50, 55.50]
54 [33, 56]
18 ( 94.7)
5 (100.0)
4 (11.1)
1 (20)
4 ( 21.1)
1 ( 20.0)
5 ( 26.3)
3 ( 60.0)
5 [3, 7.50]
2 [1, 5]
127 [120, 137]
129 [110, 133]
79 [70, 85]
65 [64, 70]
90 [83, 99]
80 [78, 89]
15 ( 78.9)
3 ( 60.0)
3 ( 15.8)
1 ( 20.0)
11 ( 57.9)
3 ( 60.0)
26.02 [22.46, 28.20]
32.66 [32.28, 32.89]
96 [82.50, 107]
5.83 [4.53, 8.55]
1.25 [1.08, 1.46]
0.65 [0.39, 0.84]
55 [38, 101]
0.08 [0.04, 0.12]
35 [27.32, 84.50]
4.52 [3.15, 7.19]
0.26 [0.13, 0.39]
0.17 [0.08, 0.18]
6 ( 37.5)
6 ( 35.3)

106 [80, 106]
7.10 [5.19, 8.06]
1.31 [1.28, 1.75]
0.94 [0.64, 1.40]
125 [74.50, 221.75]
0.16 [0.06, 0.37]
189 [184, 252]
6.89 [3.62, 9.66]
0.18 [0.13, 0.26]
0.12 [0.11, 0.16]
1 ( 20.0)
0 ( 0.0)

Table S3: Baseline characteristics stratified by viral load by cycle threshold.
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* Viral load determined by cycle threshold. A lower cycle threshold indicates a higher viral
load.

CMR Myocarditis
(specific 2018 Lake
Louis criteria)

CMR Myocarditis
(sensitive 2018 Lake
Louis criteria)

9

CMR No
Myocarditis
(specific 2018 Lake
Louis criteria)
16

13

CMR No
Myocarditis
(sensitive 2018 Lake
Louis criteria)
13

LV Ejection fraction, % (median
(IQR))
LV EDVi, ml/m2 (median (IQR))

59 [56, 62]

64 [59, 68]

59 [56, 62]

65 [59, 69]

65 [60, 73]

66 [62, 72]

62 [60, 71]

66 [65, 76]

LV ESVi, ml/m2 (median (IQR))

25 [21, 32]

22 [21, 27]

25 [21, 29]

22 [21, 28]

LV SVi, ml/m2 (median (IQR))

38 [30, 44]

44 [38, 49]

36 [32, 41]

45 [43, 49]

LV mass, g/m2 (median (IQR))

62 [57, 67]

55 [52, 58]

61 [54, 67]

56 [52, 59]

RV Ejection fraction, % (median
(IQR))
RV EDVi, ml/m2 (median (IQR))

50 [47, 58]

58 [54, 60]

52 [47, 58]

60 [53, 61]

79 [64, 83]

72 [70, 86]

71 [64, 83]

76 [71, 88]

RV ESVi, ml/m2 (median (IQR))

38 [33, 40]

32 [28, 40]

34 [32, 40]

34 [28, 44]

RV SVi, ml/m2 (median (IQR))

38 [29, 43]

43 [38, 49]

38 [30, 43]

44 [41, 49]

Global T1 - mean, ms (median
(IQR))
T1 - max, ms (median (IQR))

1270 [1241, 1302]

1279 [1264, 1321]

1269 [1241, 1302]

1276 [1259, 1322]

1342 [1301, 1403]

1372 [1322, 1414]

1342 [1299, 1407]

1369 [1325, 1415]

Global T2 - mean, ms (median
(IQR))
T2 - max, ms (median (IQR))

54 [53, 56]

49 [47, 51]

54 [52, 56]

49 [47, 51]

68 [67, 70]

58 [56, 62]

68 [64, 69]

58 [55, 62]

Global ECV, % (median (IQR))

26 [25, 28]

25 [24, 27]

26 [24, 28]

25 [24, 26]

ECV - max % (median (IQR))

n
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34 [31, 36]

29 [27, 32]

33 [30, 34]

29 [27, 32]

LGE present – n (%)

6 ( 67)

2 (12)

9 (69)

0 (0)

Sub-endocardial LGE present- n
(%)
Mid-wall LGE present- n (%)

2 ( 22)

0 ( 0)

2 (15)

0 ( 0.0)

5 ( 56)

2 (12)

8 (62)

0 ( 0.0)

Myocardial inflammatory cell
infiltration on PET - n (%)
Pulmonary Inflammation - % of
lung (median (IQR))
Pulmonary consolidation - % of
lung (median (IQR))

5 ( 62)

2 (14)

7 (58)

0 ( 0.0)

16 [2, 30]

17 [10, 31]

22 (6, 30)

17 (3, 26)

10 [8, 16]

13 [7, 18]

15 (9, 19)

11 (7, 18)

Table S4: Cardiac and pulmonary imaging parameters stratified by specific and sensitive
2018 Lake Louis criteria for myocarditis.

Tertile
n
LV Ejection fraction, % (median (IQR))

2.50 - 2.77
1
7
60 [59, 64]

Troponin
2.77 - 6.59
2
9
59 [57, 66]

>6.59
3
9
65 [56, 69]

0.696

LV EDVi, ml/m2 (median (IQR))
LV ESVi, ml/m2 (median (IQR))
LV SVi, ml/m2 (median (IQR))
LV mass, g/m2 (median (IQR))
RV Ejection fraction, % (median (IQR))

64 [61, 70]
25 [22, 26]
39 [36, 46]
54 [54, 60]
53 [48, 58]

65 [62, 71]
27 [22, 29]
40 [34, 49]
57 [52, 69]
54 [52, 59]

66 [65, 71]
21 [20, 25]
43 [30, 45]
57 [52, 61]
58 [47, 61]

0.906
0.314
0.981
0.911
0.797

71 [68, 81]
34 [30, 40]
39 [36, 41]
1277 [1260, 1302]
1317 [1306, 1387]

83 [68, 88]
36 [32, 47]
43 [37, 49]
1281 [1248, 1306]
1403 [1335, 1414]

71 [65, 79]
33 [28, 38]
43 [29, 46]
1273 [1266, 1321]
1342 [1325, 1415]

0.475
0.575
0.498
0.929
0.649

53 [48, 54]
62 [60, 66]
27 [24, 29]
32 [31, 35]
1 ( 14)
1 ( 14)
0 ( 0)
2 ( 29)
2 ( 40)
15 [9, 22]

48 [46, 49]
57 [56, 60]
24 [23, 25]
29 [27, 30]
4 ( 44)
1 ( 11)
4 ( 44)
1 ( 12)
2 ( 22)
26 [17, 38]

53 [51, 60]
67 [62, 71]
26 [25, 28]
34 [28, 34]
3 ( 33)
0 ( 0)
3 ( 33)
5 ( 56)
2 ( 25)
13 [1, 32]

0.013
0.057
0.111
0.153
0.491
0.730
0.150
0.171
0.842
0.513

13 [9, 15]

17 [9, 18]

12 [7, 18]

0.882

RV EDVi, ml/m2 (median (IQR))
RV ESVi, ml/m2 (median (IQR))
RV SVi, ml/m2 (median (IQR))
Global T1, median (median (IQR))
T1, max (median (IQR))
Global T2, median (median (IQR))
T2, max (median (IQR))
Global ECV, median (median (IQR))
ECV, max (median (IQR))
Late gadolinium enhancement (%)
Sub-endocardial LGE (%)
Mid-wall LGE (%)
Myocarditis (MRI) (%)
Myocarditis (PET) (%)
Pulmonary inflammation, % of lung
(median(IQR))
Pulmonary consolidated, % of lung
(median(IQR))

Downloaded from http://ahajournals.org by on October 5, 2022

Table S5: Cardiac and pulmonary imaging parameters stratified by troponin results
according to tertile.

p

Vascular 18F-FDG-PET/CT
Acute COVID-19

Active Controls

Historical Controls

29

5

21

Ascending aorta TBR, max SUV (mean (SD))

1.97 (0.35)

2.03 (0.06)

1.92 (0.32)

0.744

Aortic arch TBR, max SUV (mean (SD))

2.00 (0.32)

1.99 (0.15)

1.92 (0.27)

0.613

Descending aorta TBR, max SUV (mean (SD))

2.01 (0.44)

1.85 (0.07)

1.90 (0.59)

0.644

Whole aorta TBR, max SUV (mean (SD))

2.01 (0.35)

1.92 (0.08)

1.91 (0.46)

0.661

n

p

Table S6: Vascular 18F-FDG-PET TBR by aortic region comparing acute COVID-19 cases
to active and historical controls.
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Tertile
Value
n
Ascending aorta
TBR, max SUV
(mean (SD))**
Ascending aorta
TBR, mean SUV
(mean (SD))
Aortic arch TBR,
max SUV (mean
(SD))
Aortic arch TBR,
mean suv (mean
(SD))
Descending aorta
TBR, max SUV
(mean (SD))
Descending aorta
TBR, mean SUV
(mean (SD))
Whole aorta
TBR, max SUV
(mean (SD))
Whole aorta
TBR, mean SUV
(mean (SD))

CRP (mg/L)
2
[38,
100]
8
7
1.81
1.93
(0.12)
(0.18)

3
[100,
416]
9
2.13
(0.54)

1
[2.50,
2.77]
6
1.88
(0.18)

hsTroponin (ng/L)
2
[2.77,
6.59]
11
1.90
(0.17)

3
[6.59,
2637]
10
2.09
(0.54)

Cut-off
Low VL
[CT >30]
5
2.06 (0.81)

Viral Load *
Cut-off
Med VL
[CT 20-30]
17
1.99 (0.17)

Cut-off
High VL
[CT 20]
4
1.82 (0.12)

1.32
(0.08)

1.36
(0.12)

1.44
(0.21)

1.35
(0.14)

1.39
(0.13)

1.38
(0.20)

1.39 (0.30)

1.40 (0.11)

1.27 (0.03)

1.95
(0.30)

2.08
(0.27)

2.07
(0.42)

1.90
(0.29)

2.13
(0.26)

1.91
(0.39)

2.01 (0.54)

2.06 (0.27)

1.70 (0.14)

1.31
(0.10)

1.34
(0.13)

1.39
(0.22)

1.32
(0.16)

1.37
(0.11)

1.32
(0.21)

1.35 (0.30)

1.35 (0.12)

1.23 (0.07)

1.85
(0.27)

2.13
(0.38)

2.14
(0.64)

1.93
(0.38)

2.21
(0.55)

1.85
(0.30)

2.00 (0.55)

2.08 (0.45)

1.78 (0.37)

1.31
(0.12)

1.43
(0.16)

1.46
(0.24)

1.39
(0.22)

1.46
(0.18)

1.32
(0.18)

1.38 (0.20)

1.41 (0.19)

1.25 (0.16)

1.88
(0.22)

2.09
(0.27)

2.12
(0.50)

1.92
(0.28)

2.15
(0.38)

1.92
(0.35)

2.02 (0.52)

2.07 (0.33)

1.76 (0.21)

1.31
(0.09)

1.39
(0.13)

1.43
(0.21)

1.36
(0.17)

1.42
(0.14)

1.33
(0.18)

1.37 (0.24)

1.40 (0.14)

1.25 (0.09)

1
[4, 38]

Table S7: Vascular 18F-FDG-PET results stratified by CRP, hsTroponin and viral load. VL
– Viral load. CT – Cycle Threshold
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* Viral load determined by cycle threshold. A lower cycle threshold indicates a higher viral
load.
** p-value for comparing TBR by tertile of CRP, hsTrop and Viral load were 0.20, 0.44 and 0.81
respectively

Lung inflammation (%)
0% - 4%

5% - 25%

>25%

7

9

9

LV Ejection fraction, % (median (IQR))

60 [60, 64]

66 [64, 69]

57 [55, 62]

LV EDVi, ml/m2 (median (IQR))

66 [60, 76]

65 [64, 71]

66 [60, 73]

LV ESVi, ml/m2 (median (IQR))

22 [20, 33]

22 [21, 27]

26 [21, 32]

LV SVi, ml/m2 (median (IQR))

40 [32, 48]

45 [39, 49]

41 [32, 46]

LV mass, g/m2 (median (IQR))

60 [58, 64]

57 [53, 62]

56 [48, 57]

RV Ejection fraction, % (median (IQR))

58 [52, 61]

55 [52, 60]

54 [45, 59]

RV EDVi, ml/m2 (median (IQR))

70 [64, 91]

83 [74, 85]

71 [65, 79]

RV ESVi, ml/m2 (median (IQR))

33 [24, 42]

36 [32, 40]

33 [28, 47]

RV SVi, ml/m2 (median (IQR))

41 [30, 52]

44 [43, 49]

38 [35, 43]

Global T1, ms (median (IQR))

1244 [1242, 1293]

1273 [1248, 1281]

1306 [1291, 1323]

T1 max, ms (median (IQR))

1334 [1299, 1422]

1317 [1295, 1375]

1407 [1369, 1415]

Global T2, ms (median (IQR))

53 [51, 57]

49 [47, 52]

49 [48, 53]

T2 max, ms (median (IQR))

66 [58, 70]

60 [56, 63]

62 [57, 67]

Global ECV, % (median (IQR))

26 [25, 29]

25 [23, 27]

25 [24, 27]

ECV max, % (median (IQR))

30 [29, 36]

30 [27, 34]

32 [26, 34]

Late gadolinium enhancement, n (%)

3 (43)

3 (33)

3 (33)

Sub-endocardial LGE, n (%)

0 (0)

2 (22)

0 (0)

Midwall LGE, n (%)

3 (43)

2 (22)

3 (33)

RV insertion point LGE, n (%)

2 (29)

1 (11)

1 (11)

Oxygen requirement, n (%)

4 (57)

3 (33)

8 (89)

Myocarditis (MRI) (%)

3 (43)

2 (25)

3 (33)

Myocarditis (PET) (%)

3 (50)

3 (38)

1 (11)

Pulmonary consolidated, % of lung (median(IQR))

7 [4, 8]

10 [9, 16]

18 [17, 26]

n
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Table S8: Imaging parameters stratified by pulmonary inflammation

Lung Consolidation (%)
0% - 7%

7% - 15%

>15%

5

10

10

LV Ejection fraction, % (median (IQR))

60 [60, 69]

64 [60, 68]

58 [54, 64]

LV EDVi, ml/m2 (median (IQR))

66 [65, 68]

65 [64, 78]

64 [60, 72]

LV ESVi, ml/m2 (median (IQR))

22 [20, 28]

22 [21, 27]

26 [22, 30]

LV SVi, ml/m2 (median (IQR))

45 [40, 52]

44 [38, 46]

38 [32, 48]

LV mass, g/m2 (median (IQR))

59 [56, 60]

59 [54, 62]

56 [49, 62]

RV Ejection fraction, % (median (IQR))

60 [60, 62]

54 [48, 57]

54 [49, 59]

RV EDVi, ml/m2 (median (IQR))

70 [67, 74]

84 [73, 87]

74 [66, 82]

RV ESVi, ml/m2 (median (IQR))

26 [21, 30]

38 [33, 43]

36 [29, 45]

RV SVi, ml/m2 (median (IQR))

44 [41, 49]

41 [39, 48]

40 [36, 46]

Global T1, ms (median (IQR))

1266 [1244, 1273]

1273 [1244, 1311]

1297 [1271, 1317]

T1 max, ms (median (IQR))

1334 [1325, 1399]

1346 [1299, 1434]

1376 [1337, 1412]

Global T2, ms (median (IQR))

51 [49, 53]

52 [48, 54]

49 [47, 53]

T2 max, ms (median (IQR))

57 [55, 62]

64 [62, 68]

60 [57, 67]

Global ECV, % (median (IQR))

25 [24, 28]

26 [25, 28]

25 [23, 27]

ECV max, % (median (IQR))

30 [30, 34]

31 [29, 35]

30 [26, 34]

Late gadolinium enhancement, n (%)

1 ( 20)

4 (40)

4 (40)

Sub-endocardial LGE, n (%)

0 ( 0)

2 (20)

0 (0)

Midwall LGE, n (%)

1 ( 20)

3 (30)

4 (40)

RV insertion point LGE, n (%)

1 ( 20)

2 (20)

1 (10)

Oxygen requirement, n (%)

1 ( 20)

6 (60)

8 (80)

Myocarditis (MRI) (%)

1 ( 20)

4 (40)

3 (33)

Myocarditis (PET) (%)

1 ( 20)

5 (56)

1 (11)

Pulmonary inflammation, % of lung (median(IQR))

1 [1, 3]

13 [4, 17]

35 [29, 41]

n
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Table S9: Imaging parameters stratified by pulmonary consolidation
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Figure S1. Recruitment and scanning by multi-modality imaging. Of the 26 patients who had
CMR, 1 had non-diagnostic T2 imaging so could not be used for assessment of myocarditis
by the specific 2018 Lake Louis criteria. Of the 29 patients undergoing 18F-FDG PET/CT, all
could be analysed for vascular inflammation. Of the remaing patients, 25 also had a CMR for
comparison. Two patients were not adequately fasted for 18F-FDG myocardial analysis, and
1 CMR was non diagnostic, leaving 22 patients for comparison of cardiac pathology.

Figure S2. Arterial inflammation in different regions of the aorta compared to active and
historical controls.
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Figure S3. 18F-FDG PET uptake (white arrows) in the ascending aorta (a & b) and in the
liver (red arrow). Liver uptake visually higher than the aortic uptake and by consensus this
was graded at 1 using the American Society of Nuclear Cardiologists visual grading criteria.
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Black arrows may indicate possible brown fat uptake and was not considered diagnostic.

